Performance of Non-Invasive Fibrosis Tests (NITs) in MASLD Varies by Age, Diabetes, and Obesity: Results from the Global MASLD (G-MASLD) Project from the Global NASH/MASH Council (GNC)

The G-MASLD project with 18,759 biopsy-confirmed MASLD patients from 41 countries has been carried out by members of GNC. The project continues to provide critical data about MASLD/MASH and NITs from real world practices. In this analysis of G-MASLD data, the diagnostic accuracy and performance of NITs were influenced by patient characteristics. FIB-4 performance declined with younger and older age as well as presence of type 2 diabetes, while liver stiffness measurement was mainly affected by obesity. Imaging-based and clinical composite tests, especially Agile-3+ and Agile-4 showed more stable performance across subgroups.

The Global NASH/MASH Council (GNC) at Qatar Health Congress 2026 (January 29–31, 2026)

The Global NASH/MASH Council (GNC) was pleased to collaborate with Qatar Health Congress 2026 to address key topics in MASLD and MASH. The Congress was co-organized under the leadership of Professor Abdel-Naser Elzouki, Chair of the Scientific Committee and a member of the GNC, by the Department of Medicine at Hamad Medical Corporation, in collaboration with the American College of Physicians, Mayo Clinic, and the Royal Colleges of Physicians (Edinburgh, Glasgow, and London), as well as the Global NASH/MASH Council (GNC). The Congress was attended by approximately 2000 participants from Qatar, the Gulf, and across the MENA region and covered a broad range of topics in internal medicine. In collaboration with Qatar Health Congress 2026 and the Steatotic Liver Disease Research Foundation in the MENA region (SLMENA), the GNC organized a dedicated scientific session entitled “From MASLD to MASH: Advances in Diagnosis and Management.” This symposium was highly interactive and featured presentations on MASH delivered by GNC members from the region. In addition, Zobair Younossi delivered a state-of-the-art lecture entitled “The Growing Burden of MASLD and Its Management in 2026: Challenges, Innovations, and Future Directions.” The GNC is delighted to support this very important region of the world in all our activities.

Highlights from Paris International Liver Meeting 2026

The first Paris International Liver Meeting (PILM 2026) was a highly successful three-day scientific conference held from January 19–21, 2026. The meeting featured outstanding scientific sessions covering key areas including MASLD, MetALD, alcohol-associated liver disease, viral hepatitis, hepatocellular carcinoma, cholestatic liver diseases, and complications of cirrhosis. To watch the highlights from the meeting, please click the link below: